AN2 Therapeutics, Inc. — Director's Dealing 2026

Feb 23, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AN2 Therapeutics, Inc. (ANTX)
CIK: 0001880438
Period of Report: 2026-02-20

Reporting Person: Day Lucy (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-20	Common Stock	A	38000	—	Acquired	118363	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-20	Stock Option (right to buy)	$1.04	A	77000	Disposed	2036-02-19	Common Stock (77000)	Direct

Footnotes

F1: Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

F2: Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 46,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date.

F3: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025.

F4: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.